Page 18 - Morphosys News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Morphosys. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Morphosys Today - Breaking & Trending Today

Morphosys to present data on hope drug earlier

Morphosys is making faster progress than expected with research on its hopeful drug Pelabresib. Key results from the pivotal Phase 3 trial of its drug for the rare bone marrow cancer myelofibrosis. | April 4, 2023 ....

U Constellation Pharmaceuticals , Constellation Pharmaceuticals , Morphosys Ag Stock Exchange , Press Release , Ancer Mor De0006632003 ,

EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023

04.04.2023 - EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023 04.04.2023 / 22:01 CET/CEST The issuer is solely responsible . ....

United States , Italy General , Julia Neugebauer , Eamonn Nolan , Tim Demuth , Thomas Biegi , Distribution Services , Tradegate Exchange , News Service , Constellation Pharmaceuticals Inc , American Society Of Hematology , Xencor Inc , Us Oncology Network , Exchange Commission , Drug Administration , German Lymphoma Association , Sys Completes Enrollment , Topline Results Expected , Chief Research , Development Officer , Myelofibrosis Symptom Assessment Form , American Society , Constellation Pharmaceuticals , Antibody Dependent Cell Mediated Cytotoxicity , Antibody Dependent Cellular Phagocytosis , Medication Guide ,

MorphoSys Turns To Profit In Q4

MARTINSRIED (dpa-AFX) - MorphoSys AG (MOR) reported that its net profit for the fourth quarter 2022 was 329.4 million euros compared to a net loss of 381.0 million euros in the prior year. The ....

Dennis Riedl ,

MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Topline data from the Phase 3 MANIFEST-2 study expected in early 2024 Monjuvi U.S. net product sales of US$ 25.3 million (€ 24.7 million) for the fourth quarter of 2022 and US$ 89.4 million (€ 84.9 ....

United States , United Kingdom , Dennis Riedl , Julia Neugebauer , Eamonn Nolan , Lucinda Crabtree , Charlotte Lohmann , Monjuvi Minjuvi , Thomas Biegi , Jean Paul Kress , Janssen Biotech Inc , Xencor Inc , Drug Administration , Constellation Pharmaceuticals Inc , Exchange Commission , Morphosys Group Key Figures , Development Rd Expenses , Share Of Loss Associates , Chief Executive Officer , Constellation Pharmaceuticals , Sung Lee , Chief Financial Officer , Management Board , Events After , Fourth Quarter , Chief Legal Officer ,

MorphoSys Stops Pre-Clinical Research Programs; To Cut Jobs

MARTINSRIED (dpa-AFX) - German biopharmaceutical company MorphoSys AG (MOR) Thursday said it will stop work and operations on its pre-clinical research programs to optimize its cost structure. ....

Dennis Riedl , Jean Paul Kress , Paul Kress , Chief Executive Officer ,